• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

    Thumbnail
    View/ Open
    Targeting leukemic stem cell.pdf (1.638Mb)

    Show full item record
    Author
    Misaghian, Negin; Ligresti, Giovanni; Steelman, L. S.; Bertrand, Fred E.; Basecke, Jorg; Libra, Massimo; Nicoletti, Ferdinando; Stivala, F.; Milella, Michele; Tafuri, A.; Cervello, Melchiorre; Martelli, Alberto M.; McCubrey, James A.
    Abstract
    Since the discovery of leukemic stem cells (LSCs) over a decade ago, many of their critical biological properties have been elucidated, including their distinct replicative properties, cell surface phenotypes, their increased resistance to chemo-therapeutic drugs and the involvement of growthpromoting chromosomal translocations. Of particular importance is their ability to transfer malignancy to non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. Furthermore, numerous studies demonstrate that acute myeloid leukemia arises from mutations at the level of stem cell, and chronic myeloid leukemia is also a stem cell disease. In this review, we will evaluate the main characteristics of LSCs elucidated in several well-documented leukemias. In addition, we will discuss points of therapeutic intervention. Promising therapeutic approaches include the targeting of key signal transduction pathways (for example, PI3K, Rac and Wnt) with smallmolecule inhibitors and specific cell surface molecules (for example, CD33, CD44 and CD123), with effective cytotoxic antibodies. Also, statins, which are already widely therapeutically used for a variety of diseases, show potential in targeting LSCs. In addition, drugs that inhibit ATP-binding cassette transporter proteins are being extensively studied, as they are important in drug resistance â a frequent characteristic of LSCs. Although the specific targeting of LSCs is a relatively new field, it is a highly promising battleground that may reveal the Holy Grail of cancer therapy. Originally published Leukemia, Vol. 23, No. 1, Jan 2009
    URI
    http://hdl.handle.net/10342/3058
    Subject
     Drug transporters; Drug resistance; Tumor-initiating cell; Stem Cells; Targeted therapy 
    Date
    2009-01
    Citation:
    APA:
    Misaghian, Negin, & Ligresti, Giovanni, & Steelman, L. S., & Bertrand, Fred E., & Basecke, Jorg, & Libra, Massimo, & Nicoletti, Ferdinando, & Stivala, F., & Milella, Michele, & Tafuri, A., & Cervello, Melchiorre, & Martelli, Alberto M., & McCubrey, James A.. (January 2009). Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. , (. Retrieved from http://hdl.handle.net/10342/3058

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Misaghian, Negin, and Ligresti, Giovanni, and Steelman, L. S., and Bertrand, Fred E., and Basecke, Jorg, and Libra, Massimo, and Nicoletti, Ferdinando, and Stivala, F., and Milella, Michele, and Tafuri, A., and Cervello, Melchiorre, and Martelli, Alberto M., and McCubrey, James A.. "Targeting the leukemic stem cell: the Holy Grail of leukemia therapy". . . (.), January 2009. August 11, 2022. http://hdl.handle.net/10342/3058.
    Chicago:
    Misaghian, Negin and Ligresti, Giovanni and Steelman, L. S. and Bertrand, Fred E. and Basecke, Jorg and Libra, Massimo and Nicoletti, Ferdinando and Stivala, F. and Milella, Michele and Tafuri, A. and Cervello, Melchiorre and Martelli, Alberto M. and McCubrey, James A., "Targeting the leukemic stem cell: the Holy Grail of leukemia therapy,"  , no. (January 2009), http://hdl.handle.net/10342/3058 (accessed August 11, 2022).
    AMA:
    Misaghian, Negin, Ligresti, Giovanni, Steelman, L. S., Bertrand, Fred E., Basecke, Jorg, Libra, Massimo, Nicoletti, Ferdinando, Stivala, F., Milella, Michele, Tafuri, A., Cervello, Melchiorre, Martelli, Alberto M., McCubrey, James A.. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. . January 2009; () . http://hdl.handle.net/10342/3058. Accessed August 11, 2022.
    Collections
    • Microbiology and Immunology
    Publisher
    East Carolina University

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback